Integrity CE

 


 

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VRd in NDMM Eligible for ASCT”

231 views
January 24, 2024
0 Comments
Login to view comments. Click here to Login
Oncology & Hematology